Hereditary Hemorrhagic Telangiectasia Clinical Trials

Find Hereditary Hemorrhagic Telangiectasia Clinical Trials Near You

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participants are ≥18 years of age at the Screening Visit.

• Participants have a definite diagnosis of HHT by the Curaçao criteria, defined as spontaneous and recurrent epistaxis and having at least 2 of the following criteria:

‣ Multiple telangiectases at characteristic sites: lips, oral cavity, fingers, or nose;

⁃ Visceral lesions: gastrointestinal telangiectasia and/or pulmonary, hepatic, cerebral, or spinal arteriovenous malformations (AVMs); or

⁃ A first degree relative with HHT according to these criteria.

• Participants must have an ESS \>4 at screening, and, in the judgement of the Investigator, participants are expected to have regular epistaxis that typically lasts for several minutes. This criterion is assessed at screening only and does not require reconfirmation prior to randomization on Day 1.

• Participants have anemia OR in the prior 6 months have received a parenteral infusion of at least 250 mg of iron OR in the prior 6 months have received a red cell or whole blood transfusion.

Locations
United States
Illinois
The University of Chicago Medical Center (UCMC)
RECRUITING
Chicago
Indiana
Innovative Hematology, Inc.,
RECRUITING
Indianapolis
Minnesota
Mayo Clinic
RECRUITING
Rochester
Missouri
Washington University School of Medicine
RECRUITING
St Louis
Contact Information
Primary
Vaderis Therapeutics AG
info@vaderis.com
844-823-3747
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2028-06
Participants
Target number of participants: 240
Treatments
Experimental: Engasertib 40 mg
Participants will receive engasertib as an oral capsule QD for 28 weeks.
Placebo_comparator: Placebo
Participants will receive matching placebo as an oral capsule QD for 28 weeks.
Sponsors
Leads: Vaderis Therapeutics AG

This content was sourced from clinicaltrials.gov